Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in patients with heart failure. It is suggested that one of the mechanisms is its ability to block store overload-induced Calcium release which activates spontaneous calcium release by Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with calcium overload due to activation of Ryanodine receptors. The aim of this study is to evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular tachycardia(VT) originating from outflow tract.
Carvedilol is one of the third-generation beta-blockers effective in reducing ventricular arrhythmias and mortality in patients with heart failure. Antioxidative and alpha - blocking effects, along with nonselective beta - blockade, have been described as a mechanism of effect in various diseases. The antiarrhythmic effect of carvedilol inhibiting atrial fibrillation or ventricular arrhythmia has been reported, but its mechanism is not yet clear. Among them, inhibition of store overload-induced Ca2+ release (SOICR) is suggested as an antiarrhythmic mechanism of carvedilol. Stimulation of the beta receptor leads to the entry of calcium into the sarcoplasmic reticulum (SR) by opening the L-type calcium channel. The influx of calcium through the L-type calcium channel also increases the calcium release through the Ryanodine receptor (RyR) in the sarcoplasmic reticulum. This is called Ca-induced Ca release and is known as a normal physiological response. However, when calcium overload in the myofibrillar body occurs, spontaneous calcium release, known as SOICR, can occur through RyR, which can make triggered activity by inducing Na+/Ca2+ exchanger present in myocardium, leading to severe arrhythmia. Among several beta-blockers, only carvedilol has been known as a drug that can directly inhibit SOICR in combination with beta-blockade effect. Ventricular tachyarrhythmia originating from the ventricular outflow tract is an arrhythmia occurring in a patient with normal cardiac function. The mechanism of the arrhythmia is known to be triggered activity which is caused by activation of RyR due to increased cyclic adenosine monophasphate, resulting in calcium overload, eventually causing activation of Na+/Ca2+ exchanger. The aim of this study is to evaluate the efficacy of Carvedilol on PVC/VT originating from outflow tract.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
104
Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.
Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.
Keimyung University Dongsan Medical Center
Daegu, South Korea
RECRUITINGDivision of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital
Daegu, South Korea
RECRUITINGDivision of Cardiology, Department of Internal Medicine, Yeungnam University Hospital
Daegu, South Korea
RECRUITINGDivision of Cardiology, Department of Internal Medicine, Daegu Catholic University Medical Center
Daegu, South Korea
RECRUITINGChonnam National University Hospital
Gwangju, South Korea
RECRUITINGKorea University Anam Hospital
Seoul, South Korea
RECRUITINGSeoul National University Hospital
Seoul, South Korea
RECRUITINGSeverance Cardiovascular Hospital
Seoul, South Korea
RECRUITINGSeoul Asan Medical Center
Seoul, South Korea
RECRUITINGSeoul Samsung Medical Center
Seoul, South Korea
RECRUITING...and 1 more locations
PVC burden
Percentage of PVC/VT beat out of 24 hour total heart beat in Holter monitoring
Time frame: 3 months after reaching the maximum tolerated dose
Symptom assessment scale
questionnaire for PVC/VT symptoms using symptom assessment scale (Min 0 to Max 100)
Time frame: 3 months after reaching the maximum tolerated dose
Side effect of drugs
Difference in occurrence of side effects of each drug
Time frame: 3 months after reaching the maximum tolerated dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.